Curated News
By: NewsRamp Editorial Staff
June 17, 2025
Cingulate Inc. Advances ADHD Treatment with CTx-1301, Eyes $22B Market
TLDR
- Cingulate Inc.'s CTx-1301 offers a competitive edge in the $22B U.S. ADHD market with its once-daily, rapid-onset therapy, potentially outperforming existing treatments requiring booster doses.
- Cingulate Inc. utilizes its Precision Timed Release™ platform to develop CTx-1301, a once-daily ADHD treatment with proven efficacy across multiple dose levels in Phase 3 trials.
- CTx-1301 by Cingulate Inc. aims to improve ADHD treatment by offering a full-day effective therapy, enhancing patient adherence and quality of life without the need for booster doses.
- Discover how Cingulate Inc.'s innovative CTx-1301 could revolutionize ADHD treatment with its unique once-daily formula, backed by positive Phase 3 trial results.
Impact - Why it Matters
This news is significant for investors, healthcare professionals, and individuals affected by ADHD. Cingulate's CTx-1301 represents a potential breakthrough in ADHD treatment, offering a once-daily solution with rapid onset and full-day efficacy, which could significantly improve patient adherence and quality of life. The company's progress towards FDA approval and its strategic positioning in the lucrative ADHD market make it a noteworthy development in the biotech sector.
Summary
Cingulate Inc. (NASDAQ: CING) has caught the attention of investors and the healthcare sector with its innovative approach to ADHD treatment through its lead asset, CTx-1301, leveraging the proprietary Precision Timed Release™ (PTR™) platform. Stonegate Capital Partners has initiated coverage on Cingulate, highlighting the company's progress towards the commercial launch of CTx-1301, a once-daily stimulant therapy designed to offer rapid onset and sustained efficacy throughout the day, addressing the $22B U.S. ADHD market. Recent Phase 3 pediatric study results have shown statistically significant improvements in ADHD symptoms, with CTx-1301 demonstrating a strong safety profile and flexibility in administration with or without food. Cingulate is on track to submit a New Drug Application (NDA) in mid-2025, aiming to redefine ADHD treatment with the first true once-daily stimulant offering full-day efficacy.
Financially, Cingulate reported a net loss of $3.8M for 1Q25, with cash and cash equivalents standing at $9.5M. The company is exploring strategic financing options to support its NDA filing and pre-launch activities. Stonegate Capital Partners' valuation of Cingulate ranges from $13.96 to $26.96, with a midpoint of $19.09, indicating potential growth for investors. More details on the valuation can be found on the Valuation page.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Cingulate Inc. Advances ADHD Treatment with CTx-1301, Eyes $22B Market
